A Phase 1 interventional study of CBD-OS in Focal Seizures, sponsored by Jazz Pharmaceuticals. Recruiting at 24 sites in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Jazz Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing cannabidiol in Seizures — 2 open to participants now, 2 under way, none of them phase 3. Cannabidiol · Seizures.
Among the 13 studies testing cannabidiol in Seizures, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 4 in phase 1, and was the 13th registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →2 of the 13 studies testing cannabidiol in Seizures are open now, in 2 countries. Recruiting first, the newest first:
Elizabeth Donner · Sites in Canada
Ages 2–18
By country, each count listing its studies:
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 1 · Phase 3 5 · Phase 4 3
First in 2014; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 100 is above the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 61 across the 13 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 6 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
11 studies in Seizures by Jazz Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 9 finished, 5 (56%) have results posted.
Among the 11 studies in Seizures by Jazz Pharmaceuticals, this one is one of 2 that started in 2025, is the only one in phase 1, and was the 11th registered.
Jazz Pharmaceuticals’s Seizures studies by the year they started, since 2015.
1 of the studies testing cannabidiol in Seizures that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233239Jazz PharmaceuticalsA Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures | 2027-11-29 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing cannabidiol in Seizures, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jazz Pharmaceuticals’s 11 in Seizures:
This tab as a report to print or save as PDF → With an account.
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).
This study will assess the efficacy of CBD-OS as an adjunctive treatment in reducing the frequency of focal seizures compared to baseline as well as the effect of CBD-OS on health outcome endpoints in early line and refractory participants with FOS. This study will also examine pharmacokinetics (PK), safety, and potential predictors or mediators of treatment response, including functional magnetic resonance imaging (fMRI) and neuropsychological testing in a substudy.
Participants are eligible to be included in the main study only if all of the following criteria apply:
Participants are excluded from the study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who will receive open-label CBD-OS.
Drug: CBD-OS
Starting dose of CBD-OS will be administered as per the approved local product label
Also known as: GWP42003-P, JZP926
Percent change in countable focal seizure frequency compared to baseline
Time frame: Baseline up to 16 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.
Of 16 phase 1 interventional studies under Seizures, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol